Summary of Conference Call Company and Industry - **Company**: Waters Corporation - **Industry**: Life Science Tools and Diagnostics Key Points and Arguments Business Overview - The CEO, Udit Batra, emphasized the strength of the acquired BD business, noting its strong brand recognition in flow cytometry and microbiology, with gross margins around 60% [4][5] - The integration of the BD business is ongoing, with a focus on improving execution and precision in operations [5][6] Q4 Performance - BD experienced an 11% decline in Q4, attributed to three non-recurring items and one recurring item, leading to flat growth when adjusted [10][11] - The recurring item, DRG headwinds in China, is expected to persist into the current year, impacting guidance [11][12] Future Guidance - For Q1, a decline of 2.5% is anticipated, with expectations of flat to low single-digit growth in Q2 and Q3, and low to mid-single-digit growth in Q4 [11][12] - The CEO expressed confidence in achieving EPS growth commitments despite current challenges [12] Bioscience Business - The bioscience business was down 10%, underperforming compared to market expectations, which should have been low to mid-single digits [15][16] - The CEO highlighted the need for improved precision in management and execution to address underperformance [23][24] Pricing Strategy - The bioscience business has been passing on only 0-50 basis points of pricing, which is below expectations given its differentiated portfolio [25][26] - The CEO emphasized the importance of focusing on pricing improvements and distribution strategies [25][26] Core Waters Business - The core Waters business is expected to grow organically at 6.25% in 2026, with strong performance in chemistry and service segments [32][36] - New product launches and improved service attachment rates are anticipated to drive growth [38][39] LC-MS Replacement Cycle - The LC-MS replacement cycle is expected to return to high single digits by mid-2027, with ongoing discussions about reshoring contributing to growth [41][46] Margin Expectations - BD's operating margin is projected to normalize around 22.4%, with cost adjustments and tariff implementations expected to contribute positively [72][86] - The CEO noted that pricing improvements are necessary to achieve desired margins, with current pricing at 50 basis points [86] Organizational Focus - The CEO plans to focus on specific business areas, particularly the reagents business, while ensuring accountability and support for teams [92][96] - Cross-pollination of successful strategies among teams is encouraged to enhance overall performance [96] Additional Important Content - The CEO highlighted the importance of precision in forecasting and execution, particularly in response to external challenges such as government shutdowns [14][23] - There is a strong emphasis on the engagement and energy within the organization, with a commitment to improving operational efficiencies and customer relationships [8][90]

Investment Rating - The investment rating for Zhejiang Longsheng is maintained at OVERWEIGHT with a target price of RMB 11.88, indicating a potential upside of 21% from the closing price of RMB 9.85 as of May 13, 2025 [1][8]. Core Insights - Zhejiang Longsheng reported a 1Q25 revenue of RMB 3.24 billion, with an attributable net profit of RMB 0.40 billion, reflecting a year-on-year increase of 100.4% in net profit, primarily driven by its property business [1]. - The company is expected to benefit from a recovery in demand for dye and intermediate products, alongside continued revenue contributions from its property operations [1]. - The gross margin improved by 1.5 percentage points year-on-year to 28.6% in 1Q25, attributed to decreased raw material costs [2]. - The property segment is entering a monetization phase, with significant projects like the Huaxing New Town and Domus project showing strong sell-through rates [3]. Financial Performance - For 2025, the attributable net profit estimates are maintained at RMB 2,145 million, with projected earnings per share (EPS) of RMB 0.66 [4]. - Revenue is expected to grow from RMB 15,303 million in 2023 to RMB 17,709 million in 2025, representing an 11.49% increase [6]. - The company’s financial metrics indicate a projected PE ratio of 15.03 for 2025, which is above the peers' average of 15x [4][6].